A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

Summary

The purpose of this study was to assess the safety and tolerability of RO7200220 as monotherapy (diabetic macular edema \[DME\] or uveitic macular edema \[UME\] population) and in combination with ranibizumab (DME population only).

Timeline

Start

2019-07-22

Primary completion

2023-11-13

Completion

2023-11-13

Publications

• Sharma S, Lin P, Hu A, Suhler EB, Pauly-Evers M, Holmes W, Barekati Z, Willen D, Macgregor L, Steeples L, Haskova Z, Feenstra D, Silverman D, Passemard B, Fauser S, Mesquida M. Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial. JAMA Ophthalmol. 2026 May 1;144(5):442-451. doi: 10.1001/jamaophthalmol.2026.0610.

Drugs

Indications